Table 9.
Results of subgroup analysis and interaction analysis
| Characteristic | No of participants | HR (95%CI) | P for interacion | β(95%CI) | P for interaction |
|---|---|---|---|---|---|
| Age (years) | 0.07 | 0.30 | |||
| < 60 (years) | 177 | 0.81 (0.54, 1.20) | -0.60 (-2.01, 0.81) | ||
| ≥ 60 (years) | 577 | 0.53 (0.37, 0.75) | -1.41 (-2.19, -0.63) | ||
| Gender | 0.21 | 0.11 | |||
| Male | 522 | 0.64 (0.47, 0.89) | -0.97 (-1.80, -0.13) | ||
| Female | 232 | 0.41 (0.22, 0.76) | -2.15 (-3.37, -0.94) | ||
| Urinary occult blood | 0.64 | < 0.05 | |||
| No | 511 | 0.53 (0.34, 0.80) | -0.84 (-1.72, 0.04) | ||
| Yes | 243 | 0.60 (0.40, 0.91) | -2.37 (-3.39, -1.36) | ||
| BMI (kg/m2) | 0.10 | 0.96 | |||
| < 23.5 | 381 | 0.45 (0.30, 0.68) | -1.61 (-2.50, -0.72) | ||
| ≥ 23.5 | 373 | 0.72 (0.47, 1.10) | -1.58 (-2.57, -0.59) | ||
| UPCR (g/gCr) | 0.97 | 0.17 | |||
| < 3.5 | 595 | 0.59 (0.38, 0.91) | -1.47 (-2.29, -0.64) | ||
| ≥ 3.5 | 159 | 0.58 (0.41, 0.84) | -2.43 (-3.58, -1.27) | ||
| Etiology of CKD | < 0.05 | 0.13 | |||
| Diabetic nephropathy | 182 | 0.86 (0.56, 1.32) | -1.79 (-3.17, -0.40) | ||
| Nephrosclerosis, | 305 | 0.23 (0.12, 0.44) | -1.69 (-2.82, -0.57) | ||
| Glomerulonephritis | 147 | 0.52 (0.21, 1.25) | -1.49 (-3.13, 0.15) | ||
| Other | 120 | 1.80 (0.69, 4.68) | 0.29 (-1.22, 1.80) | ||
| Use of RAAS inhibitor | 0.63 | 0.22 | |||
| No | 250 | 0.71 (0.39, 1.31) | -1.92 (-3.02, -0.82) | ||
| Yes | 504 | 0.61 (0.43, 0.85) | -1.11 (-1.94, -0.27) | ||
| Hypertension | 0.42 | 0.85 | |||
| No | 71 | 0.28 (0.04, 1.97) | -1.56 (-3.82, 0.70) | ||
| Yes | 683 | 0.61 (0.45, 0.82) | -1.33 (-2.07, -0.59) | ||
| History of CVD | 0.42 | 0.94 | |||
| No | 561 | 0.68 (0.46, 1.00) | -1.42 (-2.24, -0.60) | ||
| Yes | 193 | 0.54 (0.36, 0.81) | -1.47 (-2.50, -0.45) | ||
| Diabetes | 0.09 | 0.13 | |||
| No | 477 | 0.49 (0.33, 0.72) | -1.72 (-2.56, -0.89) | ||
| Yes | 277 | 0.73 (0.51, 1.06) | -0.68 (-1.82, 0.48) | ||
| Use of CCB | 0.64 | 0.26 | |||
| No | 373 | 0.65 (0.45, 0.93) | -1.81 (-2.74, -0.89) | ||
| Yes | 381 | 0.58 (0.41, 0.84) | -1.09 (-2.05, -0.14) | ||
| Use of diuretics | 0.96 | 0.24 | |||
| No | 515 | 0.59 (0.40, 0.87) | -1.11 (-1.97, -0.26) | ||
| Ye | 239 | 0.60 (0.41, 0.89) | -1.91 (-3.00, -0.83) | ||
| CKD stage | 0.63 | 0.51 | |||
| 2 | 62 | 0.44 (0.12, 1.62) | -1.04 (-3.65, 1.56) | ||
| 3 | 327 | 0.56 (0.36, 0.87) | -0.61 (-1.77, 0.56) | ||
| 4 | 250 | 0.69 (0.48, 1.01) | -1.82 (-3.00, -0.65) | ||
| 5 | 115 | 0.80 (0.47, 1.35) | -1.30 (-3.20, 0.59) |
Note 1: Above model adjusted for gender, age, BMI, hypertension, history of CVD, diabetes, SBP, eGFR, UPCR, Hb, use of RAAS inhibitor, urinary occult blood, use of calcium channel blocker and use of diuretics
Note 2: In each case, the model is not adjusted for the stratification variable